223 related articles for article (PubMed ID: 25365349)
21. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.
Yang YS; Zhang X; Xiong Z; Chen X
Nucl Med Biol; 2006 Apr; 33(3):371-80. PubMed ID: 16631086
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
Hanaoka H; Tominaga H; Yamada K; Paudyal P; Iida Y; Watanabe S; Paudyal B; Higuchi T; Oriuchi N; Endo K
Ann Nucl Med; 2009 Aug; 23(6):559-67. PubMed ID: 19504168
[TBL] [Abstract][Full Text] [Related]
23. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
[TBL] [Abstract][Full Text] [Related]
24. CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model.
Son CH; Bae JH; Shin DY; Lee HR; Choi YJ; Jo WS; Ho Jung M; Kang CD; Yang K; Park YS
J Immunother; 2014 Jan; 37(1):1-7. PubMed ID: 24316550
[TBL] [Abstract][Full Text] [Related]
25. Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models.
Iida Y; Harashima N; Motoshima T; Komohara Y; Eto M; Harada M
Cancer Sci; 2017 Oct; 108(10):1974-1984. PubMed ID: 28787548
[TBL] [Abstract][Full Text] [Related]
26. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
27. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
McBride WJ; Zanzonico P; Sharkey RM; Norén C; Karacay H; Rossi EA; Losman MJ; Brard PY; Chang CH; Larson SM; Goldenberg DM
J Nucl Med; 2006 Oct; 47(10):1678-88. PubMed ID: 17015905
[TBL] [Abstract][Full Text] [Related]
28. Detection of early stage atherosclerotic plaques using PET and CT fusion imaging targeting P-selectin in low density lipoprotein receptor-deficient mice.
Nakamura I; Hasegawa K; Wada Y; Hirase T; Node K; Watanabe Y
Biochem Biophys Res Commun; 2013 Mar; 433(1):47-51. PubMed ID: 23485468
[TBL] [Abstract][Full Text] [Related]
29. A novel PET imaging using ⁶⁴Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells.
Kobayashi K; Sasaki T; Takenaka F; Yakushiji H; Fujii Y; Kishi Y; Kita S; Shen L; Kumon H; Matsuura E
J Immunol Res; 2015; 2015():268172. PubMed ID: 25883990
[TBL] [Abstract][Full Text] [Related]
30. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
31. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
32. PET/CT Based In Vivo Evaluation of 64Cu Labelled Nanodiscs in Tumor Bearing Mice.
Huda P; Binderup T; Pedersen MC; Midtgaard SR; Elema DR; Kjær A; Jensen M; Arleth L
PLoS One; 2015; 10(7):e0129310. PubMed ID: 26132074
[TBL] [Abstract][Full Text] [Related]
33. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies.
Liu S; Li D; Park R; Liu R; Xia Z; Guo J; Krasnoperov V; Gill PS; Li Z; Shan H; Conti PS
J Nucl Med; 2013 Jul; 54(7):1094-100. PubMed ID: 23667241
[TBL] [Abstract][Full Text] [Related]
34. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein.
Miao Z; Ren G; Liu H; Jiang L; Cheng Z
Bioconjug Chem; 2010 May; 21(5):947-54. PubMed ID: 20402512
[TBL] [Abstract][Full Text] [Related]
35. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
Petersen AL; Binderup T; Jølck RI; Rasmussen P; Henriksen JR; Pfeifer AK; Kjær A; Andresen TL
J Control Release; 2012 Jun; 160(2):254-63. PubMed ID: 22245688
[TBL] [Abstract][Full Text] [Related]
36. Validation of 64Cu-DOTA-rituximab injection preparation under good manufacturing practices: a PET tracer for imaging of B-cell non-Hodgkin lymphoma.
Natarajan A; Arksey N; Iagaru A; Chin FT; Gambhir SS
Mol Imaging; 2015; 14():. PubMed ID: 25762106
[TBL] [Abstract][Full Text] [Related]
37. Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy.
Larimer BM; Wehrenberg-Klee E; Caraballo A; Mahmood U
J Nucl Med; 2016 Oct; 57(10):1607-1611. PubMed ID: 27230929
[TBL] [Abstract][Full Text] [Related]
38. An EGFR targeted PET imaging probe for the detection of colonic adenocarcinomas in the setting of colitis.
Turker NS; Heidari P; Kucherlapati R; Kucherlapati M; Mahmood U
Theranostics; 2014; 4(9):893-903. PubMed ID: 25057314
[TBL] [Abstract][Full Text] [Related]
39. Imaging tumor vasculature noninvasively with positron emission tomography and RGD peptides labeled with copper 64 using the bifunctonal chelates DOTA, oxo-DO3a. and PCTA.
Yapp DT; Ferreira CL; Gill RK; Boros E; Wong MQ; Mandel D; Jurek P; Kiefer GE
Mol Imaging; 2013 Jun; 12(4):263-72. PubMed ID: 23651504
[TBL] [Abstract][Full Text] [Related]
40. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors.
Velikyan I; Sundberg AL; Lindhe O; Höglund AU; Eriksson O; Werner E; Carlsson J; Bergström M; Långström B; Tolmachev V
J Nucl Med; 2005 Nov; 46(11):1881-8. PubMed ID: 16269603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
